Hideaki Shiraishi1,2, Yutaka Fujiwara1,3, Takanori Kakuya4, Koji Tsuta5, Noriko Motoi5, Nami Miura4, Yukio Watabe4, Shun-Ichi Watanabe6, Rintaro Noro4, Kengo Nagashima7, Wilber Huang8, Tesshi Yamada4, Hisao Asamura9, Yuichiro Ohe1,2, Kazufumi Honda4,10. 1. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. 2. Department of Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. 3. Department of Experimental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital, Tokyo, Japan. 4. Division of Chemotherapy & Clinical Research, National Cancer Center Research Institute, Tokyo, Japan. 5. Pathology & Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. 7. Department of Global Clinical Research, Graduate School of Medicine, Chiba University, Chiba, Japan. 8. Abnova Corporation, Taipei, Taiwan. 9. General Thoracic Surgery, School of Medicine, Keio University, Tokyo, Japan. 10. Japan Agency for Medical Research & Development: AMED-CREST, AMED, Tokyo, Japan.
Abstract
AIM: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. MATERIALS & METHODS: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. RESULTS: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. CONCLUSION: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.
AIM: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. MATERIALS & METHODS: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. RESULTS: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. CONCLUSION: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinomapatients.
Authors: Alexandra Surcel; Eric S Schiffhauer; Dustin G Thomas; Qingfeng Zhu; Kathleen T DiNapoli; Maik Herbig; Oliver Otto; Hoku West-Foyle; Angela Jacobi; Martin Kräter; Katarzyna Plak; Jochen Guck; Elizabeth M Jaffee; Pablo A Iglesias; Robert A Anders; Douglas N Robinson Journal: Cancer Res Date: 2019-07-29 Impact factor: 13.312